W
wannabemogger
Iron
- Joined
- Aug 3, 2023
- Posts
- 137
- Reputation
- 116
1. PTH 1-34 (Teriparatide)
Mechanism:
An anabolic bone agent that stimulates osteoblast activity and increases bone remodeling. Mimics parathyroid hormone—intermittent dosing leads to bone formation, not resorption.
Target Zone:
Growth plates (epiphyseal regions of long bones: femur, tibia).
Injection Type:
- Subperiosteal (under the periosteum near tibial epiphysis).
- 27–30G insulin syringe.
- Angle: ~30°, just under the skin, sliding toward the bone.
Dosage:
- 20 µg/day or split into 10 µg AM/PM
- 5 days on / 2 days off
Pros:
- Proven to increase bone density and formation
- Synergistic with IGF-1 and BMP-2
- Readily available as Forteo or biosimilars
Cons:
− Long-term use may cause desensitization
− Mild nausea or hypercalcemia risk
− Expensive without insurance
2. BMP-2 (Bone Morphogenetic Protein-2)
Mechanism:
BMP-2 triggers mesenchymal stem cell differentiation into osteoblasts, catalyzing new bone growth via endochondral ossification. It's what your body uses after fractures.
Target Zone:
Tibial shaft, spinal processes, or femur near growth-active zones.
Injection Type:
- Subperiosteal + Hydrogel scaffold
- BMP-2 must be mixed into a sterile hydrogel (like GelMA, PEG-based, or HA-based) for localized delivery.
- Inject directly against bone beneath the periosteum with a 1 mL syringe, 27G needle.
Dosage:
- 2–10 µg per site
- Frequency: 1–2x/week
- Rotate limbs to prevent saturation/osteolysis
Pros:
- Direct bone mass and length gains
- Triggers natural bone morphogenesis
- Synergizes with PTH, VEGF-A165
Cons:
− Risk of ectopic bone if misplaced
− Osteolysis if overdosed
− Needs a proper scaffold for efficacy
3. VEGF-A165 (Vascular Endothelial Growth Factor A)
Mechanism:
Drives angiogenesis, blood vessel growth into growth plates and periosteum. Enhances nutrient delivery and speeds up endochondral ossification. Helps vascularize BMP-2 sites.
Target Zone:
Same as BMP-2—epiphyseal regions and periosteal zones of tibia or femur.
Injection Type:
- Subperiosteal or intradermal over bone zones
- 27–31G insulin syringe
- Combine with BMP-2 or IGF-1 DES for max effect
Dosage:
- 2–5 µg/site
- 2–3x/week, alternate sites
Pros:
- Increases BMP-2 and IGF-1 response
- Improves vascularization of graft zones
- Good for stacking with growth factors
Cons:
− Must be dosed carefully to avoid aberrant angiogenesis
− May cause edema if overdosed
Final Notes:
- Cycle example: 8–12 weeks on, 4 weeks off
- Ideal stack: PTH 1-34 (daily), BMP-2 (weekly), VEGF-A165 (3x/week)
- Recovery support: BPC-157, MSC exosomes
- Avoid training 2–4 hours after injections for osteogenesis window.
